Exemed Gets CDSCO Panel Nod To study dapagliflozin, Sacubitril, Valsartan as Sodium salt tablet
New Delhi: Exemed Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the bioequivalence (BE) study and Phase III clinical trial of the fixed-dose combination (FDC) of Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg/5mg/5mg plus Sacubitril and Valsartan as Sodium salt complex 50mg (24mg and 26mg), 100mg (49mg and 51mg) and 200mg (97mg and 103mg) tablet.
This came after the firm presented its proposal along with the BE study protocol and Phase III clinical trial protocol before the committee.
The combined use of sacubitril/valsartan and dapagliflozin is associated with improved cardiac function in patients affected by heart failure (HF) with reduced ejection fraction (HFrEF).
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor. Sodium-glucose cotransporter 2 is responsible for the reabsorption of approximately 90% of the urinary glucose in the proximal tubule of the nephron. Inhibition of SGLT2 induces glucosuria, which is more pronounced in hyperglycemic individuals owing to the higher amounts of glucose filtered into the urine. The effect of glucosuria diminishes with the normalizing of blood glucose levels. Among individuals with HFrEF, with or without diabetes mellitus, the addition of dapagliflozin has been associated with decreased rates of cardiovascular (CV) death or worsening heart failure (HF), as well as all-cause mortality
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.